Inspire Medical Systems (NYSE:INSP) Price Target Lowered to $85.00 at Mizuho

Inspire Medical Systems (NYSE:INSP) had its target price cut by Mizuho from $130.00 to $85.00 in a research report sent to investors on Thursday morning, MarketBeat reports. They currently have an outperform rating on the stock.

INSP has been the topic of several other reports. Stifel Nicolaus set a $110.00 price objective on Inspire Medical Systems and gave the company a “buy” rating in a research note on Monday, November 24th. Wolfe Research upgraded shares of Inspire Medical Systems from a “peer perform” rating to an “outperform” rating and set a $180.00 price target on the stock in a research note on Tuesday, November 25th. Morgan Stanley reissued an “equal weight” rating and issued a $130.00 target price (up from $105.00) on shares of Inspire Medical Systems in a report on Tuesday, December 2nd. UBS Group set a $96.00 target price on shares of Inspire Medical Systems in a research note on Thursday, January 22nd. Finally, Zacks Research upgraded shares of Inspire Medical Systems from a “strong sell” rating to a “hold” rating in a research report on Monday, October 27th. Six equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $110.65.

Inspire Medical Systems Trading Down 12.4%

INSP stock opened at $59.74 on Thursday. Inspire Medical Systems has a 12-month low of $53.11 and a 12-month high of $197.75. The stock has a market cap of $1.74 billion, a price-to-earnings ratio of 12.00, a PEG ratio of 6.88 and a beta of 0.74. The business’s 50-day moving average is $94.42 and its 200 day moving average is $91.48.

Inspire Medical Systems (NYSE:INSP) last issued its earnings results on Wednesday, February 11th. The company reported $1.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.96. Inspire Medical Systems had a return on equity of 11.47% and a net margin of 15.95%.The company had revenue of $269.08 million during the quarter, compared to analysts’ expectations of $264.02 million. During the same period in the prior year, the business earned $1.15 EPS. The firm’s quarterly revenue was up 12.2% on a year-over-year basis. As a group, equities analysts forecast that Inspire Medical Systems will post 2.16 EPS for the current fiscal year.

Insider Activity at Inspire Medical Systems

In related news, Director Shawn Mccormick sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $127.48, for a total value of $254,960.00. Following the sale, the director directly owned 26,046 shares of the company’s stock, valued at approximately $3,320,344.08. This trade represents a 7.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 4.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Inspire Medical Systems

Several hedge funds and other institutional investors have recently modified their holdings of INSP. HRT Financial LP increased its position in shares of Inspire Medical Systems by 166.5% in the fourth quarter. HRT Financial LP now owns 121,761 shares of the company’s stock worth $11,230,000 after acquiring an additional 76,080 shares in the last quarter. Brooklyn Investment Group purchased a new stake in shares of Inspire Medical Systems during the 4th quarter valued at about $307,000. Renaissance Technologies LLC grew its position in Inspire Medical Systems by 165.0% in the fourth quarter. Renaissance Technologies LLC now owns 410,768 shares of the company’s stock valued at $37,885,000 after acquiring an additional 255,768 shares in the last quarter. Counterpoint Mutual Funds LLC raised its stake in shares of Inspire Medical Systems by 30.0% during the fourth quarter. Counterpoint Mutual Funds LLC now owns 5,488 shares of the company’s stock valued at $506,000 after purchasing an additional 1,267 shares during the period. Finally, EntryPoint Capital LLC purchased a new stake in shares of Inspire Medical Systems during the fourth quarter valued at approximately $222,000. 94.91% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Inspire Medical Systems

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Q4 results beat and operational strength — Inspire posted $269.1M in Q4 revenue (↑12% y/y) and adjusted EPS of $1.65, topping estimates; gross margin expanded and operating cash flow and buybacks support cash returns. Earnings Release
• Neutral Sentiment: Full earnings package and call are available for deeper read — slide deck and transcript provide detail on assumptions behind the 2026 outlook and tax/adjustment impacts for modeling. Slide Deck / Press Release Call Transcript
• Negative Sentiment: Guidance cut and coding/reimbursement uncertainty — management narrowed FY2026 revenue to $950M–$1.0B and said the Inspire V procedure will likely transition to CPT 64582 with a -52 modifier, potentially lowering physician reimbursement and pressuring procedure volumes. That guidance revision is the primary driver of the selloff. MSN: Revenue Outlook & Coding
• Negative Sentiment: Immediate market reaction — analysts and headlines highlighted the coding/guidance risk and shares fell sharply despite the beat. Zacks: Stock Falls Despite Q4 Beat Investing.com: Shares Slide
• Negative Sentiment: Analyst price-target resets — multiple firms lowered targets (Jefferies to $66, Truist to $70, Mizuho to $85, Piper Sandler to $85) which increases near-term downside pressure even when some ratings remain constructive. Benzinga: Analyst Actions The Fly: Mizuho PT Cut
• Negative Sentiment: Bearish analysis and investor concerns — independent commentary highlights lingering risks around reimbursement, growth cadence and margin sustainability, reinforcing the negative sentiment. Seeking Alpha: Critical Take

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.